Nami Surgical has secured 拢3.2 million funding to transform the robotic-assisted surgery market.
The Glasgow startup, behind a breakthrough ultrasonic platform, has secured 拢2.5m of investment from Eos Advisory alongside the Investment Fund for Scotland, which is managed by Maven and delivered by British 老九品茶 Bank, Scottish Enterprise and SIS Ventures.
The company has separately been awarded a 拢700,000 grant from Innovate UK.
Nami Surgical develops miniaturised ultrasonic medical devices for surgical applications, and supports medical device companies to deliver innovation in ultrasonic surgery. In a groundbreaking development, Nami has introduced a high-performance, miniaturised ultrasonic scalpel, overcoming significant barriers in robotic-assisted surgery.聽
Traditionally favoured in laparoscopic procedures, ultrasonic scalpels have been too large for effective use in robotic surgery until now.
Robotic surgeries, characterised by enhancing surgical precision and dexterity, significantly reduce patient trauma, post-operative pain, and recovery times, leading to shorter hospital stays.聽
鈥淩obot-assisted surgery has become increasingly popular in recent years and is now widely used in various surgical procedures including urology, gynaecology, and colorectal,鈥� said CEO and co-founder Nico Fenu.聽
鈥淲e have pilot programmes running with healthcare and medical device groups worldwide, including in the United States, and we now look forward to the commercialisation phase with the support of our new investors.鈥�
The company was co-founded by CTO Dr Rebecca Cleary in 2022 and is chaired by experienced life science and MedTech non-exec director Albert Nicholl.聽
He said: 鈥淲e have a huge opportunity ahead of us, and a fast route to market with the first product from the platform.鈥�
Fenu added: 鈥淲e are committed to close collaboration with clinicians and companies in the industry to translate their needs into novel devices that not only improve patient outcomes, but also drive ultrasonic surgery to the next level. It’s an exciting time for us, and we are just getting started.鈥�